Global Resilience
We coined the term TechBio to capture the rise of innovation where technology meets biology. Today, Global Resilience is the next horizon, driven by founders leveraging tools like AI to create new markets or transform existing ones. From pandemic response to national security infrastructure, resilience is no longer siloed. It’s a unified field—and an urgent one.
Our focus is frontier: technologies that strengthen health and security. These tools safeguard critical infrastructure, enable faster response to public health threats, power next-generation cell therapies, and drive global intelligence.
At ARTIS, we believe that connecting with the world's most brilliant minds transforms good companies into legendary ones.
Our journey has been driven by a global network of leaders and visionaries across our Healthcare Alliance, Pioneers Network, and Fellows Program.
Why Tech Bio+Health
Affecting everyday people
At ARTIS we invest in data-driven life sciences companies that solve problems affecting everyday people from across the globe. We care about scalable medical technologies backed by engineering, AI and strong datasets with broad indications for healthcare and life sciences.
Flexibility to pivot
Investing in companies with a Tech Bio+Health thesis ensures a plethora of indications from a singular biologically engineered approach, opening the door for increased revenue streams, optionality, intellectual property and flexibility to pivot in times of need.
Engineering-first approach
By combining the best of computer science and the powers of cellular biology, Tech Bio+Health is the engineering-first approach that enables cures instead of treatments, personalized therapeutics, more efficient drug discovery and powerful AI-machine led exploration of biological circuitry.
Companies that create new markets or redefine existing ones
